Search Result

Results for "

RANKL

" in MedChemExpress (MCE) Product Catalog:

By Targets:	RANKL/RANK (8) Akt (3) Antibiotic (1) Apoptosis (2) Autophagy (2) Bacterial (3) Btk (1) Calcineurin (1) CXCR (1) ERK (1) FGFR (1) GLUT (1) HIV (1) HMG-CoA Reductase (HMGCR) (1) Insulin Receptor (1) LXR (1) Macrophage migration inhibitory factor (MIF) (1) MEK (1) NF-κB (9) Nuclear Factor of activated T Cells (NFAT) (3) p38 MAPK (1) Phosphatase (1) PI3K (1) PIN1 (1) Prostaglandin Receptor (2) PROTACs (1) Proton Pump (1) Reactive Oxygen Species (1) STAT (1) STING (1)
By Research Areas:	Cancer (13) Cardiovascular Disease (3) Endocrinology (1) Infection (6) Inflammation/Immunology (12) Metabolic Disease (7) Neurological Disease (3)

By Targets:

RANKL/RANK (8)

Akt (3)

Antibiotic (1)

Apoptosis (2)

Autophagy (2)

Bacterial (3)

Btk (1)

Calcineurin (1)

CXCR (1)

ERK (1)

FGFR (1)

GLUT (1)

HIV (1)

HMG-CoA Reductase (HMGCR) (1)

Insulin Receptor (1)

LXR (1)

Macrophage migration inhibitory factor (MIF) (1)

MEK (1)

NF-κB (9)

Nuclear Factor of activated T Cells (NFAT) (3)

p38 MAPK (1)

Phosphatase (1)

PI3K (1)

PIN1 (1)

Prostaglandin Receptor (2)

PROTACs (1)

Proton Pump (1)

Reactive Oxygen Species (1)

STAT (1)

STING (1)

By Research Areas:

Cancer (13)

Cardiovascular Disease (3)

Endocrinology (1)

Infection (6)

Inflammation/Immunology (12)

Metabolic Disease (7)

Neurological Disease (3)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Antibodies

Targets Recommended: RANKL/RANK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P9958

Denosumab 1 Publications Verification Immunoglobulin G2; Ranmark	NF-κB	Cancer
Denosumab is a human monoclonal antibody binding to, and inhibiting, the receptor activator of *RANKL* (TNFSF11). Denosumab can reduce the risk of vertebral, nonvertebral and hip fractures , also has anti-cancer activity .

HY-147369

NFATc1-IN-1 1 Publications Verification	Nuclear Factor of activated T Cells (NFAT)	Others
NFATc1-IN-1 (compound A04) is a potent inhibitor of RANKL-induced osteoclast formation, with an IC₅₀ of 1.57 μM. NFATc1-IN-1 shows anti-osteoclastogenic effects through reducing the RANKL-induced nuclear translocation of NFATc1. NFATc1-IN-1 can be used for osteoclastic diseases research .

HY-N10838

Ajudecunoid A

Others Others

Ajudecunoid A is nature product that could be isolated from Ajuga decumbens. Ajudecunoid A inhibits RANKL-Induced osteoclastogenesis .

Ajudecunoid A	Others	Others
Ajudecunoid A is nature product that could be isolated from Ajuga decumbens. Ajudecunoid A inhibits RANKL-Induced osteoclastogenesis .

HY-155960

SH491	Others	Inflammation/Immunology
SH491 (Compound 33) is an antiosteoporosis agent. SH491 inhibits RANKL-induced osteoclast differentiation on bone-marrow-derived monocytes (BMMs) (IC₅₀: 11.8 nM). SH491 inhibits the expression of osteoclastogenesis-related marker genes (TRAP, CTSK, MMP-9, and ATPase v0d2) and proteins (TRAP, CTSK, MMP-9) .

HY-149472

Anti-osteoporosis agent-4	NF-κB PI3K	Inflammation/Immunology
Anti-osteoporosis agent-4 (Compound 11h) inhibits differentiation of primary osteoclasts. Anti-osteoporosis agent-4 attenuates RANKL-induced osteoclastogenesis. Anti-osteoporosis agent-4 inhibits osteoclast formation with an IC₅₀ value of 358.29 nM. Anti-osteoporosis agent-4 inhibits PI3K/AKT and IκBα/NF-κB signaling pathway activation .

HY-130304

8-Isoprostaglandin E2 iPE2-III	Prostaglandin Receptor	Cardiovascular Disease
8-Isoprostaglandin E2 (iPE2-III) is a member of the isoprostane class of prostanoids. 8-Isoprostaglandin E2 acts at the receptor for thromboxane A₂ (the TP) in vivo to induce vasoconstriction and platelet aggregation. 8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway .

HY-N0277

Aconine 2 Publications Verification Jesaconine	NF-κB	Inflammation/Immunology Cancer
Aconine inhibits receptor activator of nuclear factor (NF)-κB ligand (RANKL)-induced NF-κB activation.

HY-P99966

Narlumosbart

RANKL/RANK Cancer

Narlumosbart (JMT103) is an IgG4κ antibody targeting receptor activator of nuclear factor-κB ligand (RANKL) .

Narlumosbart	RANKL/RANK	Cancer
Narlumosbart (JMT103) is an IgG4κ antibody targeting receptor activator of nuclear factor-κB ligand (RANKL) .

HY-N11514

Anti-osteoporosis agent-2	Others	Inflammation/Immunology
Anti-osteoporosis agent-2 (Compound 10) is an anti-osteoporosis agent. Anti-osteoporosis agent-2 inhibits differentiation on osteoclast induced by RANKL .

HY-N10117

2,3-Bis(3-indolylmethyl)indole	RANKL/RANK	Others
2,3-Bis(3-indolylmethyl)indole significantly suppresses RANKL-induced osteoclast formation, actin ring formation, and bone resorption in a concentration-dependent manner.

HY-N10062

Amakusamine	RANKL/RANK	Others
Amakusamine inhibits the receptor activator of nuclear factor-κB ligand (RANKL)-induced formation of multinuclear osteoclasts with an IC₅₀ value of 10.5 μM in RAW264.7 cells.

HY-110063

4-IPP 2 Publications Verification 4-Iodo-6-phenylpyrimidine	Macrophage migration inhibitory factor (MIF)	Metabolic Disease
4-IPP (4-Iodo-6-phenylpyrimidine) is a specific suicide substrate and irreversible inhibitor of macrophage migration inhibitory factor (MIF) .

HY-N12740

Napyradiomycin B4	MEK ERK	Others
Napyradiomycin B4 is a Napyradiomycin derivative, which inhibits the RANKL-induced MEK-ERK signaling pathway. Napyradiomycin B4 attenuates osteoclastogenesis and prevents alveolar bone destruction in experimental periodontitis .

HY-N2119

Sciadopitysin
Sciadopitysin is a type of biflavonoids in leaves from ginkgo biloba . Sciadopitysi inhibits RANKL-induced osteoclastogenesis and bone loss by inhibiting NF-κB activation and reducing the expression of c-Fos and NFATc1 .

HY-153675

BCPA	PIN1	Metabolic Disease
BCPA is a Pin1 regulator without cytotoxicity. BCPA attenuates the reduction of Pin1 protein to inhibit receptor activator of RANKL-induced osteoclastogenesis. BCPA regulates osteoclast activation, used to osteoporosis research .

HY-N3188

Niloticin	Akt NF-κB	Infection
Niloticin, tetracyclic triterpenoid compound, is a osteoclastogenesis inhibitor. Niloticin shows anti-viral, antioxidative, and mosquitocidal activities. Niloticin inhibits osteoclastogenesis by blocking RANKL-RANK interaction and suppressing the AKT, MAPK, and NF-κB signaling pathways .

HY-N9346

Phlorigidoside C

Others Inflammation/Immunology

Phlorigidoside C, a natural iridoid glucoside, possesses anti-rheumatoid arthritis effect .

Phlorigidoside C	Others	Inflammation/Immunology
Phlorigidoside C, a natural iridoid glucoside, possesses anti-rheumatoid arthritis effect .

HY-N0499

Cyanidin Chloride 2 Publications Verification IdB 1027	RANKL/RANK	Cancer
Cyanidin Chloride (IdB 1027), a subclass of anthocyanin, displays antioxidant and anti-carcinogenesis properties. Cyanidin Chloride (IdB 1027) inhibits osteoclast formation, hydroxyapatite resorption, and receptor activator of NF-κB ligand (RANKL)-induced osteoclast marker gene expression .

HY-N0656

Usnic acid 1 Publications Verification	Bacterial	Infection Cancer
Usnic acid, a lichen-derived secondary metabolite, has a unique dibenzofuran skeleton. Usnic acid has excellent anticancer and antimicrobial properties. Usnic acid significantly inhibits RANKL-mediated osteoclast formation and function by reducing the transcriptional and translational expression of NFATc1 .

HY-P9958A

Denosumab (anti-TNFSF11) 1 Publications Verification	RANKL/RANK	Cancer
Denosumab (anti-TNFSF11) is a RANKL inhibitor that is effective against giant cell tumor of bone (GCTB).Denosumab eliminates RANK-positive tumor giant cells and reduces the relative content of proliferative, dense-cell tumor stromal cells .

HY-N11775

Eudebeiolide B Plebeiolide D	NF-κB Akt Nuclear Factor of activated T Cells (NFAT) Phosphatase	Metabolic Disease
Eudebeiolide B is a compound that can be isolated from Salvia plebeia R. Br. Eudebeiolide B inhibits osteoclastogenesis by regulating *RANKL*-induced NF-κB, c-Fos and calcium signaling. Eudebeiolide B can be used for osteoclast-related diseases research .

HY-N12507

Eupenicisirenin C	STING NF-κB	Others
Eupenicisirenin C (compound 1) is a sirenin derivative. Eupenicisirenin C has strong NF-κB inhibitory activities. Eupenicisirenin C suppresses effects on cGAS-STING pathway. Eupenicisirenin C inhibits RANKL-induced osteoclast differentiation in bone marrow macrophage cells .

HY-158098

FGFR1 inhibitor-11	FGFR	Metabolic Disease
FGFR1 inhibitor-11 (compound 5g) binds to FGFR1, inactivation of its downstream ERK1/2 and IκBα/NF-κB signaling inhibited RANKL-induced osteoclastogenesis. FGFR1 inhibitor-11 has oral bioactivity .

HY-118482

Sauristolactam Saurolactam	Others	Neurological Disease
Sauristolactam, a natural aristolactam isolated from aerial portions of Saururus chinensis, has significant neuroprotective activity against glutamate-induced toxicity in primary cultured rat cortical cells . Sauristolactam also inhibits the receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis and has the potential to inhibit osteoclast differentiation .

HY-125911

Gossypin	NF-κB	Cardiovascular Disease Inflammation/Immunology Cancer
Gossypin is a flavone isolated from Hibiscus vitifolius and has antioxidant, antiinflammatory, anticancer, anticataract, antidiabetic, and hepatoprotective activities. Gossypin inhibits NF-κB and NF-κB-regulated gene expression. Gossypin inhibits RANKL-induced osteoclastogenesis both in mouse primary bone marrow cells and RAW 264.7 cells in vitro .

HY-130237

Cinnamtannin B-1	Reactive Oxygen Species	Metabolic Disease Cancer
Cinnamtannin B-1 is a proanthocyanidin with multiple biological functions, including antioxidant effects and inhibiting the production of reactive oxygen species (ROS). Cinnamtannin B-1 inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced osteoporosis in vivo. Cinnamtannin B-1 can be used for the research osteoporosis and colon cancers .

HY-152262

LXRβ agonist-4	LXR	Inflammation/Immunology
LXRβ agonist-4 is a potent, orally active Liver X receptors (LXRs) agonist with an IC₅₀ value of 0.0078 μM for LXRβ. LXRβ agonist-4 inhibits RANKL-induced osteoclast differentiation and bone resorption. LXRβ agonist-4 can be used in research of osteoporosis .

HY-N12604

Penicisteck acid F	NF-κB	Others
Penicisteck acid F (Compound 2) is a Marine derived tanzanic acid derivative that is a NF-κB inhibitor. Penicisteck acid F inhibits osteoclast expression by decreasing RANKL-induced IκBα degradation, NF-κB p65 nuclear translocation, NFATc1 activation and nuclear translocation, and related mRNA expression. Penicisteck acid F can be used in osteoporosis research .

HY-113756A

Latanoprost acid 1 Publications Verification	Prostaglandin Receptor	Inflammation/Immunology
Latanoprost acid, an analog of prostaglandin (PG) F2α, is an selective prostanoid receptor (FP) agonist that specifically activates the FP-PG receptor . Latanoprost acid inhibits RANKL-induced osteoclastgenesis and function by inhibiting ERK, AKT, JNK, and p38 cascade, following by the c-fos/NFATc1 pathway. Latanoprost acid is a medication which works to lower pressure inside the eyes .

HY-B1246

Thonzonium bromide 5 Publications Verification	Bacterial Proton Pump	Infection
Thonzonium bromide is an antibacterial agent that is structurally similar to Farnesol (HY-Y0248A). Thonzonium bromide is also a monocationic surface-active agent, which inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Thonzonium bromide inhibits proton transport in a dose-dependent manner (EC₅₀=69 μM) .

HY-N6973R

Boldine (Standard)	RANKL/RANK	Inflammation/Immunology
Boldine (Standard) is the analytical standard of Boldine. This product is intended for research and analytical applications. Boldine is an aporphine isoquinoline alkaloid extracted from the root of Litsea cubeba and also possesses these properties, including antioxidant, anti-inflammatory and cytoprotective effects. Boldine suppresses osteoclastogenesis, improves bone destruction by down-regulating the *OPG/RANKL/RANK* signal pathway and may be a potential therapeutic agent for rheumatoid arthritis .

HY-162280

PROTAC BTK Degrader-9	PROTACs RANKL/RANK Nuclear Factor of activated T Cells (NFAT) Btk	Cancer
PROTAC BTK Degrader-9 (compound 23) is a PROTAC degrader that effectively targets BTK. PROTAC BTK Degrader-9 downregulates the BTK-PLCγ2-Ca ²⁺-NFATc1 signaling pathway activated by RANKL. Thus, PROTAC BTK Degrader-9 was able to inhibit osteoclastogenesis and attenuate alveolar bone resorption in a mouse periodontitis model .

HY-110318

VUF11207 fumarate 1 Publications Verification	CXCR	Inflammation/Immunology Cancer
VUF11207 fumarate is a CXCR7 agonist that binds specifically to CXCR7. VUF11207 fumarate reduces CXCL12-mediated osteoclastogenesis and bone resorption by inhibiting ERK phosphorylation .

HY-N0751

Scutellarin Maximum Cited Publications 9 Publications Verification	STAT Akt HIV	Infection Cancer
Scutellarin, an active flavone isolated from Scutellaria baicalensis, can down-regulates the STAT3/Girdin/Akt signaling in HCC cells, and inhibits RANKL-mediated MAPK and NF-κB signaling pathway in osteoclasts. Scutellarin is active against HIV-1IIIB, HIV-1(74V) and HIV-1KM018 with EC₅₀s of 26 μM, 253 μM and 136 μM, respectively.

HY-N1746

(2S)-2'-Methoxykurarinone 2'-O-Methylkurarinone
(2S)-2'-Methoxykurarinone, a compound isolated from the roots of Sophora flavescens, has anti-inflammatory, antipyretic, antidiabetic, and antineoplastic effects. (2S)-2'-Methoxykurarinone (MK) inhibits osteoclastogenesis and bone resorption through down-regulation of RANKL signaling. (2S)-2'-Methoxykurarinone (MK) displays cytotoxic activity against human myeloid leukemia HL-60 cells .

HY-N6973

Boldine	RANKL/RANK Apoptosis	Inflammation/Immunology
Boldine is an apomorphine isoquinoline alkaloid extracted from the root of the pheasant pepper (Litsea cubeba). Boldine is an oral effective antioxidant, anti-inflammatory, antitumor agent, and can inhibit osteoclast formation. Boldine induces apoptosis of human bladder cancer cells by regulating ERK, AKT and GSK-3β. Boldine ameliorates bone destruction by down-regulating the *OPG/RANKL/RANK* signaling pathway. It can be used in rheumatoid arthritis research .

HY-17408

Mevastatin 5+ Cited Publications Compactin; ML236B	HMG-CoA Reductase (HMGCR) Bacterial Autophagy Apoptosis Antibiotic	Infection Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Mevastatin (Compactin) is a first HMG-CoA reductase inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces apoptosis, arrests cancer cells in G₀/G₁ phase. Mevastatin also increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels. Mevastatin has antitumor activity and has the potential for cardiovascular diseases treatment .

HY-N9736

6,4'-Dihydroxy-7-methoxyflavanone	Calcineurin	Infection Neurological Disease Inflammation/Immunology
6,4'-Dihydroxy-7-methoxyflavanone, a flavonoid, is a nature product that could be isolated from Heartwood Dalbergia odorifera. 6,4'-Dihydroxy-7-methoxyflavanone inhibits receptor activators of nuclear factor kappa-B ligand (RANKL) induced osteoclastogenesis. 6,4'-Dihydroxy-7-methoxyflavanone has antioxidant, anti-inflammatory and neuroprotective effects. 6,4'-Dihydroxy-7-methoxyflavanone can be used in research of osteoporosis .

HY-N0755

Rhoifolin	Insulin Receptor GLUT NF-κB p38 MAPK Autophagy	Metabolic Disease Endocrinology Cancer
Rhoifolin is a flavone glycoside can be isolated from Rhus succedanea. Rhoifolin has anti-diabetic effect acting through enhanced adiponectin secretion, tyrosine phosphorylation of insulin receptor-β and glucose transporter 4 (GLUT 4) translocation. Rhoifolin has an anti-inflammatory action via multi-level regulation of inflammatory mediators. Rhoifolin ameliorates titanium particle-stimulated osteolysis and attenuates osteoclastogenesis via RANKL-induced NF-κB and MAPK pathways. Rhoifolin also has cytotoxic activity against different cancer cell lines .

Cat. No.	Product Name	Target	Research Area

HY-P9958

Denosumab 1 Publications Verification Immunoglobulin G2; Ranmark	NF-κB	Cancer
Denosumab is a human monoclonal antibody binding to, and inhibiting, the receptor activator of *RANKL* (TNFSF11). Denosumab can reduce the risk of vertebral, nonvertebral and hip fractures , also has anti-cancer activity .

HY-P9958A

Denosumab (anti-TNFSF11) 1 Publications Verification	RANKL/RANK	Cancer
Denosumab (anti-TNFSF11) is a RANKL inhibitor that is effective against giant cell tumor of bone (GCTB).Denosumab eliminates RANK-positive tumor giant cells and reduces the relative content of proliferative, dense-cell tumor stromal cells .

HY-P990165

*Anti-Mouse RANKL/CD254 Antibody (IK22/5)*	Inhibitory Antibodies	Others
Anti-Mouse RANKL/CD254 Antibody (IK22/5) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse RANKL/CD254.

HY-P99966

Narlumosbart

RANKL/RANK Cancer

Narlumosbart (JMT103) is an IgG4κ antibody targeting receptor activator of nuclear factor-κB ligand (RANKL) .

Narlumosbart	RANKL/RANK	Cancer
Narlumosbart (JMT103) is an IgG4κ antibody targeting receptor activator of nuclear factor-κB ligand (RANKL) .

Aconine 2 Publications Verification Jesaconine	Alkaloids Classification of Application Fields Source classification Ranunculaceae Aconitum carmichaeli Debx. Plants Disease Research Fields Cancer	NF-κB
Aconine inhibits receptor activator of nuclear factor (NF)-κB ligand (RANKL)-induced NF-κB activation.

Recombinant Proteins Recommended:

RANKL

Species:	Human (5) Mouse (4) Cynomolgus (1)
Tag:	His (3) Tag Free (3) Fc (4) Flag (2)
Source:	HEK293 (7) CHO (1) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P73386

	RANKL/TNFSF11 Protein, Human (HEK293) 1 Publications Verification Tumor necrosis factor ligand superfamily member 11; RANKL; CD254; ODF; OPGL; TNFSF11; TRANCE	Human	HEK293
	RANKL (TNFSF11), a type II transmembrane protein, is a receptor activator of NF-κB (RANK) ligand. RANKL is an activator of RANK. When binding to RANK, it induces the differentiation of monocyte/macrophage-lineage cells into osteoclasts and leads to osteoclast precursor maturation. RANKL is critical for osteoclasts maturation, bone modeling, and bone remodeling, as well as the development of lymph nodes (LNs). RANKL/TNFSF11 Protein, Human (HEK293) is a recombinant human RANKL (G64-D245) without any tag, which is produced in HEK293 cell.

HY-P73388

	RANKL/TNFSF11 Protein, Mouse (HEK293, Fc) 1 Publications Verification Tumor necrosis factor ligand superfamily member 11; RANKL; CD254; ODF; OPGL; TNFSF11; TRANCE	Mouse	HEK293
	RANKL (TNFSF11), a type II transmembrane protein, is a receptor activator of NF-κB (RANK) ligand. RANKL is an activator of RANK. When binding to RANK, it induces the differentiation of monocyte/macrophage-lineage cells into osteoclasts and leads to osteoclast precursor maturation. RANKL is critical for osteoclasts maturation, bone modeling, and bone remodeling, as well as the development of lymph nodes (LNs). RANKL/TNFSF11 Protein, Mouse (HEK293, Fc) is a recombinant mouse RANKL (R72-D316) with N-terminal hFc tag, which is produced in HEK293.

HY-P75999

	RANKL/TNFSF11 Protein, Cynomolgus (HEK293, Fc) Tumor necrosis factor ligand superfamily member 11; RANKL; CD254; ODF; OPGL; TNFSF11; TRANCE	Cynomolgus	HEK293
	RANKL (TNFSF11), a type II transmembrane protein, is a receptor activator of NF-κB (RANK) ligand. RANKL is an activator of RANK. When binding to RANK, it induces the differentiation of monocyte/macrophage-lineage cells into osteoclasts and leads to osteoclast precursor maturation. RANKL is critical for osteoclasts maturation, bone modeling, and bone remodeling, as well as the development of lymph nodes (LNs). RANKL/TNFSF11 Protein, Human (HEK293, hFc) is a recombinant human RANKL (G63-D244) with N-terminal hFc tag, which is produced in HEK293.

HY-P7424

	RANKL/TNFSF11 Protein, Human 5 Publications Verification rHuRANK L/TNFSF11; TRANCE; CD254	Human	E. coli
	RANKL (TNFSF11), a type II transmembrane protein, is receptor activator of NF-κB (RANK) ligand. RANKL is an activator of RANK. When binding to RANK, it induces the differentiation of monocyte/macrophage-lineage cells into osteoclasts and leads to osteoclast precursor maturation. RANKL is critical for osteoclasts maturation, bone modeling, and bone remodeling, as well as the development of lymph nodes (LNs). RANKL/TNFSF11 Protein, Human is a recombinant human RANKL (I140-D317) without any tag, which is produced in E.coli.

HY-P73387

	RANKL/TNFSF11 Protein, Human (HEK293, hFc) Tumor necrosis factor ligand superfamily member 11; RANKL; CD254; ODF; OPGL; TNFSF11; TRANCE	Human	HEK293
	RANKL (TNFSF11), a type II transmembrane protein, is a receptor activator of NF-κB (RANK) ligand. RANKL is an activator of RANK. When binding to RANK, it induces the differentiation of monocyte/macrophage-lineage cells into osteoclasts and leads to osteoclast precursor maturation. RANKL is critical for osteoclasts maturation, bone modeling, and bone remodeling, as well as the development of lymph nodes (LNs). RANKL/TNFSF11 Protein, Human (HEK293, hFc) is a recombinant human RANKL (G64-D245) with N-terminal hFc tag, which is produced in HEK293.

HY-P7425

	RANKL/TNFSF11 Protein, Mouse 3 Publications Verification rMuRANK L/TNFSF11; TRANCE; CD254	Mouse	E. coli
	RANKL (TNFSF11), a type II transmembrane protein, is a receptor activator of NF-κB (RANK) ligand. RANKL is an activator of RANK. When binding to RANK, it induces the differentiation of monocyte/macrophage-lineage cells into osteoclasts and leads to osteoclast precursor maturation. RANKL is critical for osteoclasts maturation, bone modeling, and bone remodeling, as well as the development of lymph nodes (LNs). RANKL/TNFSF11 Protein, Mouse is a recombinant mouse RANKL (Q137-D316) without tag, which is produced in E.coli.

HY-P73682

	RANK L/TNFSF11 Protein, Human (HEK293, mFc) Tumor necrosis factor ligand superfamily member 11; ODF; RANKL; CD254; TNFSF11	Human	HEK293
	RANKL (TNFSF11), a type II transmembrane protein, is a receptor activator of NF-κB (RANK) ligand. RANKL is an activator of RANK. When binding to RANK, it induces the differentiation of monocyte/macrophage-lineage cells into osteoclasts and leads to osteoclast precursor maturation. RANKL is critical for osteoclasts maturation, bone modeling, and bone remodeling, as well as the development of lymph nodes (LNs). RANKL/TNFSF11 Protein, Human (HEK293, Fc) is a recombinant human RANKL (G63-D244) with N-terminal mFc tag, which is produced in HEK293 cell.

HY-P78376

	RANKL/TNFSF11 Protein, Human (HEK293, His-Flag) ODF; OPGL; RANKL; TRANCE; CD254; sOdf; TNFSF11; OPTB2	Human	HEK293
	RANKL (TNFSF11), a type II transmembrane protein, is a receptor activator of NF-κB (RANK) ligand. RANKL is an activator of RANK. When binding to RANK, it induces the differentiation of monocyte/macrophage-lineage cells into osteoclasts and leads to osteoclast precursor maturation. RANKL is critical for osteoclasts maturation, bone modeling, and bone remodeling, as well as the development of lymph nodes (LNs). RANKL/TNFSF11 Protein, Human (HEK293, hFc) is a recombinant human RANKL (G63-D244) with N-terminal his and flag tag, which is produced in HEK293.

HY-P700259

	RANKL/TNFSF11 Protein, Mouse (CHO, His) rMuRANKL/TNFSF11, His; TRANCE; CD254	Mouse	CHO
	RANKL/TNFSF11 Protein, Mouse (CHO) is a TNF-related activation-induced cytokine produced in CHO. Mouse and human RANK Ligand share 85% amino acid identity. RANK L/TNFSF11 Protein, Mouse (CHO, His) induces the activation of the c-jun N terminal kinase, enhances T cell growth and dendritic cell function, induces osteoclastogenesis, and lymph node organogenesis.

HY-P7425C

	RANKL/TNFSF11 Protein, Mouse (HEK293, His, Flag) soluble Receptor Activator of NF-kB Ligand; TNFSF11; TRANCE (TNF-Related Activation-induced Cytokine); OPGL; ODF (Osteoclast Differentiation Factor); CD254; sRNAK Ligand	Mouse	HEK293

Cat. No.	Product Name	Application	Reactivity

HY-P81124

RANKL/CD254 Antibody OPGL; CD254; hRANKL2; ODF; OPGL; Osteoclast differentiation factor; Osteoprotegerin ligand; RANKL; Receptor activator of nuclear factor kappa B ligand; sOdf; SOFA; TNF related activation induced cytokine; TNFSF 11; TNFSF11; TRANCE; Tumor necrosis factor ligand superfamily member 11; Osteoprotegerin Ligand; TNF11_HUMAN.	WB; ELISA; IHC-P; IHC-F; Flow-Cyt; IF	Human, Mouse(predicted: Rat, Dog)
RANKL/CD254 Antibody is an unconjugated, approximately 35 kDa, rabbit-derived, anti-RANKL/CD254 polyclonal antibody. RANKL/CD254 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, mouse, and predicted: rat, dog background without labeling.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks